5-氨基-2-氟苯硼酸 | 873566-74-6

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯硼酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-2-氟苯硼酸
• 英文名称: 5-amino-2-fluorophenylboronic acid
• 英文别名: (5-amino-2-fluorophenyl)boronic acid
• CAS: 873566-74-6
• 化学式: C₆H₇BFNO₂
• mdl: MFCD03411555
• 分子量: 154.936
• InChiKey: CDZMVORRMKESPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-氨基-2-氟苯硼酸 、 3-(4-chloro-6-morpholin-4-yl-pyrimidin-2-yl)-phenol 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.25h， 生成 4-(3-amino-6-fluorophenyl)-2-(3-hydroxyphenyl)-6-morpholinopyrimidine
  参考文献：
  名称：

  [EN] 2, 4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER
  [FR] PYRIMIDINES 2,4,6-TRISUBSTITUTEES UTILISEES COMME INHIBITEURS DE PHOSPHOTIDYLINOSITOL (PI) 3-KINASE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER

  摘要：

  该发明涉及式（I）的嘧啶衍生物，其中p，R1，R2，q，R3，r，R4，X1和Q1中的每一个具有描述中定义的任何含义；它们的制备过程，含有它们的制药组合物以及它们在制造用于在温血动物如人中产生抗增殖效应的药物的制药中的使用。

  公开号：

  WO2006005918A1

文献信息

• 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors
  申请人：Arrien Pharmaceuticals LLC

  公开号：US20140315909A1

  公开（公告）日：2014-10-23

  The present invention relates to compounds described by Formula I: salts thereof, their synthesis, and their use as ITK and JAK3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, Crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention.

  本发明涉及由式I描述的化合物： 其盐，它们的合成，以及它们作为ITK和JAK3抑制剂的用途，包括这些化合物以及使用这些化合物治疗各种疾病和/或疾病的方法，这些疾病与异常细胞生长有关，如自身免疫、炎症、类风湿关节炎、系统性红斑狼疮、动脉粥样硬化、溃疡性结肠炎、银屑病性关节炎、银屑病、克罗恩病、代谢和癌症疾病。本发明还提供包括本发明化合物的药学上可接受的组合物以及使用这些组合物的方法和制备本发明化合物的方法。
• Discovery of Selective 4-Amino-pyridopyrimidine Inhibitors of MAP4K4 Using Fragment-Based Lead Identification and Optimization
  作者：Terry D. Crawford、Chudi O. Ndubaku、Huifen Chen、Jason W. Boggs、Brandon J. Bravo、Kelly DeLaTorre、Anthony M. Giannetti、Stephen E. Gould、Seth F. Harris、Steven R. Magnuson、Erin McNamara、Lesley J. Murray、Jim Nonomiya、Amy Sambrone、Stephen Schmidt、Tanya Smyczek、Mark Stanley、Philip Vitorino、Lan Wang、Kristina West、Ping Wu、Weilan Ye

  DOI：10.1021/jm500155b

  日期：2014.4.24

  implicated in the regulation of many biological processes. A fragment-based lead discovery approach was used to generate potent and selective MAP4K4 inhibitors. The fragment hit pursued in this article had excellent ligand efficiency (LE), an important attribute for subsequent successful optimization into drug-like lead compounds. The optimization efforts eventually led us to focus on the pyridopyrimidine

  丝裂原活化的蛋白激酶激酶激酶激酶4（MAP4K4）是一种丝氨酸/苏氨酸激酶，与许多生物过程的调控有关。基于片段的线索发现方法用于生成有效的和选择性的MAP4K4抑制剂。本文追求的碎片命中具有出色的配体效率（LE），这是随后成功优化成药物样先导化合物的重要属性。优化工作最终使我们专注于吡啶并嘧啶系列，从中鉴定出6-（2-氟吡啶-4-基）吡啶[3,2 - d ]嘧啶-4-胺（29）。该化合物具有低纳摩尔浓度，优异的激酶选择性和良好的体内暴露，并且在人肿瘤异种移植模型中显示出体内药效学作用。
• NHC-Copper Mediated Ligand-Directed Radiofluorination of Aryl Halides
  作者：Liam S. Sharninghausen、Allen F. Brooks、Wade P. Winton、Katarina J. Makaravage、Peter J. H. Scott、Melanie S. Sanford

  DOI：10.1021/jacs.0c02637

  日期：2020.4.22

  which the C(sp2)-18F bond is formed via a copper-mediated pathway. Copper N-heterocyclic carbene complexes serve as mediators for this transformation, using aryl halide substrates with directing groups at the ortho position. This reaction is applied to the radiofluorination of electronically diverse aryl halide derivatives, including the bioactive molecules vismodegib and PH-089.

  [18F] 标记的芳基氟化物被广泛用作正电子发射断层扫描 (PET) 成像的放射性示踪剂。芳基卤化物 (ArX) 是这些放射性示踪剂特别有吸引力的前体，因为它们易于获得、价格低廉且稳定。然而，迄今为止，从芳基卤化物直接制备 [18F]-芳基氟化物仍然仅限于高度活化的 ArX 底物和 K18F 之间的 SNAr 反应。本报告描述了一种芳基卤化物放射性氟化反应，其中 C(sp2)-18F 键是通过铜介导的途径形成的。铜 N-杂环卡宾配合物用作这种转化的介体，使用在邻位具有导向基团的芳基卤化物底物。该反应适用于电子不同的芳基卤化物衍生物的放射性氟化，
• [EN] MACROCYCLIC LRRK2 KINASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DE KINASES LRRK2
  申请人：ONCODESIGN SA

  公开号：WO2016042089A1

  公开（公告）日：2016-03-24

  The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

  本发明涉及公式（I）的新型大环化合物及含有该化合物的组合物，作为激酶抑制剂，特别是作为LRRK2（富含亮氨酸重复激酶2）的抑制剂。此外，本发明提供了制备所述化合物的方法，以及使用它们的方法，例如作为药物或诊断试剂，特别用于治疗和/或诊断由LRRK2激酶活性特征化的疾病，如包括帕金森病和阿尔茨海默病在内的神经系统紊乱。
• Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: Heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay
  作者：Thota Ganesh、Pahk Thepchatri、Lian Li、Yuhong Du、Haian Fu、James P. Snyder、Aiming Sun

  DOI：10.1016/j.bmcl.2008.08.022

  日期：2008.9

  Heat shock protein 90 is emerging as an important target in cancer chemotherapy. In a program directed toward identifying novel chemical probes for Hsp90, we found N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)benzene sulfonamide as an Hsp90 inhibitor with very weak activity. In this report, we present a new and general method for the synthesis of a variety of analogs around this scaffold, and discuss their structure-activity relationships. (C) 2008 Elsevier Ltd. All rights reserved.